Abstract | BACKGROUND: METHODS: RESULTS: Eleven children were entered on the protocol. Six patients had extragonadal disease, five patients had ovarian primaries. Seven patients had low-stage tumor (I or II) and four had advanced-stage tumor (III or IV). Three of six evaluable patients attained a complete response at 21 weeks. Three patients with a residual soft tissue mass at restaging underwent further therapy. No patient has relapsed after a median of 51 (range 14-88) months of follow-up. CONCLUSIONS:
|
Authors | A L Frazier, H E Grier, D M Green |
Journal | Medical and pediatric oncology
(Med Pediatr Oncol)
Vol. 27
Issue 2
Pg. 69-73
(Aug 1996)
ISSN: 0098-1532 [Print] United States |
PMID | 8649322
(Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Dactinomycin
- Vincristine
- Etoposide
- Cyclophosphamide
- Cisplatin
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Child
- Child, Preschool
- Cisplatin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Dactinomycin
(administration & dosage)
- Drug Administration Schedule
- Endodermal Sinus Tumor
(drug therapy)
- Etoposide
(administration & dosage)
- Female
- Humans
- Infant
- Treatment Outcome
- Vincristine
(administration & dosage)
|